Related Experiment Video
Updated: May 11, 2026
07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
An update on idiopathic pulmonary fibrosis
G A Margaritopoulos1, I Giannarakis, N M Siafakas
1Interstitial Lung Disease Unit, University Hospital of Heraklion, Crete, Greece. gmargaritop@yahoo.gr
Panminerva Medica
|May 17, 2013
Summary
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease. Early diagnosis and new treatments like pirfenidone offer hope for managing IPF progression.
Area of Science:
- Pulmonology and Fibrotic Lung Diseases
- Pathophysiology of Idiopathic Pulmonary Fibrosis
Background:
- Idiopathic pulmonary fibrosis (IPF) is a severe, progressive fibrotic lung disease with a poor prognosis.
- The exact pathophysiology of IPF is not fully understood, but type II alveolar epithelial cell injury is a critical initiating event.
- Early diagnosis is crucial for potentially slowing disease progression.
Purpose of the Study:
- To highlight the importance of accurate diagnosis in managing Idiopathic Pulmonary Fibrosis.
- To discuss recent advancements in IPF diagnosis and treatment.
- To emphasize the significance of multidisciplinary collaboration in IPF diagnosis.
Main Methods:
- Review of current understanding of IPF pathophysiology.
- Discussion of diagnostic improvements through multidisciplinary disease meetings (pulmonologists, radiologists, pathologists).
- Highlighting the recent licensing of pirfenidone as an IPF-specific drug.
Main Results:
- Multidisciplinary meetings have enhanced diagnostic confidence for IPF.
- Pirfenidone, the first IPF-specific drug, is now licensed in key global markets.
- Early intervention may reduce disease progression in IPF patients.
Conclusions:
- Accurate and timely diagnosis of IPF is essential for patient management.
- The development and licensing of pirfenidone represent a significant milestone in IPF treatment.
- Continued research into IPF pathophysiology is needed for further therapeutic advancements.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.